Trial-related discrimination in HIV vaccine clinical trials

被引:44
作者
Allen, M
Israel, H
Rybczyk, K
Pugliese, MA
Loughran, K
Wagner, L
Erb, S
机构
[1] NIAID, Bethesda, MD 20892 USA
[2] St Louis Univ, Sch Med, St Louis, MO 63104 USA
[3] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA
[4] Univ Rochester, Sch Med, Rochester, NY 14642 USA
[5] EMMES Corp, Potomac, MD 20854 USA
关键词
D O I
10.1089/088922201750236942
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Participants in preventive HIV vaccine trials may experience negative social consequences of trial participation, including problems related to a vaccine-induced positive HIV antibody test, yet few vaccine studies have reported on this issue. From October 1995 through November 1998, 1516 AIDS Vaccine Evaluation Group (AVEG) volunteers were assessed for reports of trial-related discrimination (TRD), Ninety TRD events were reported by 76 (5%) of 1516 volunteers, The most commonly reported incidents (n = 52, 57.8%) were negative reactions of friends, family, and co-workers to the volunteer. Few incidents (approximately 10%) were reported as linked to HIV testing. The majority of events (n = 47, 52%) were described by volunteers as "resolved" at the time of reporting, 36 (40%) as "not resolved," and for 7 (8%) events: volunteers did not report resolution status. Reported incidents were analyzed by logistic regression to determine their association with the volunteer's age, sex, race, sexual orientation, and HIV risk category. There was no association between volunteer characteristics and TRD, Logistic regression and analysis of variance (ANOVA) were used to analyze association of trial sites with the number of TRD events reported. After controlling for site variation in data collection and reporting, no significant differences were found between the sites in terms of the number or type of TRD reported. Fears that TRD would be widespread and severe have not been borne out by this analysis. While the results of this study are reassuring, they should be interpreted with caution, as it is unclear whether these results may be extended to phase III trials enrolling large numbers of individuals at higher risk of HIV acquisition.
引用
收藏
页码:667 / 674
页数:8
相关论文
共 23 条
  • [1] *AIDS ACT FDN, 1994, HIV PREV VACC SOC ET
  • [2] [Anonymous], SEARCH AIDS VACCINE
  • [3] INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS
    BELSHE, RB
    CLEMENTS, ML
    KEEFER, MC
    GRAHAM, BS
    COREY, L
    SPOSTO, R
    WESCOTT, S
    LAWRENCE, D
    GORSE, GJ
    KENNEDY, D
    FREY, S
    LAMBERT, J
    SCHWARTZ, D
    DOLIN, R
    ROBERTS, N
    MCELRATH, J
    COOMBS, J
    WRIGHT, P
    KARZON, D
    FAST, P
    WALKER, MC
    MESTECKY, J
    JACKSON, S
    STABLEIN, D
    WOLFF, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1994, 121 (08) : 584 - +
  • [4] WILLINGNESS TO PARTICIPATE IN AIDS VACCINE TRIALS AMONG HIGH-RISK POPULATIONS IN NORTHERN THAILAND
    CELENTANO, DD
    BEYRER, C
    NATPRATAN, C
    EIUMTRAKUL, S
    SUSSMAN, L
    RENZULLO, PO
    KHAMBOONRUANG, C
    NELSON, KE
    [J]. AIDS, 1995, 9 (09) : 1079 - 1083
  • [5] Risk behavior for HIV infection in participants in preventive HIV vaccine trials: A cautionary note
    Chesney, MA
    Chambers, DB
    Kahn, JO
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (04): : 266 - 271
  • [6] DOUGLAS JM, 1994, AIDS RES HUM RETROV, V10, pS257
  • [7] ERB S, 1998, COMMUNICATION
  • [8] Graham B S, 1990, Infect Dis Clin North Am, V4, P223
  • [9] Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines
    Gross, M
    Seage, GR
    Mayer, KH
    Goldstein, RS
    Losina, E
    Wold, C
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 12 (04): : 406 - 412
  • [10] SCIENTIFIC AND SOCIAL-ISSUES OF HUMAN-IMMUNODEFICIENCY-VIRUS VACCINE DEVELOPMENT
    HAYNES, BF
    [J]. SCIENCE, 1993, 260 (5112) : 1279 - 1286